Clinical Trial Update: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

The update covers a Phase 1 study of TILT-123, an oncolytic adenovirus, in combination with pembrolizumab for refractory non-small cell lung cancer. The trial s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TILT-123 (tilt-123)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING